Hetero Research Foundation
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
1
Ending by 2030
May 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 2, 2027The maintenance fee for Crystalline form of Eltrombopag free acid (US 10,336,706) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 1 fee due Feb 4, 2027The maintenance fee for Amorphous ritonavir co-precipitated (US 9,096,556) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
- 2 fees due Mar 8 to 22, 2027 · next Mar 8
- 2 fees due Apr 13 to 15, 2027 · next Apr 13
- 1 fee due May 3, 2027The maintenance fee for Crystalline Hydrochloride Salt of Darunavir (US 9,175,005) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Rilpivirine hydrochloride (US 9,233,935) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,175,005 | Crystalline Hydrochloride Salt of Darunavir In force · High confidence | In force | High confidence | |
| US 8,912,333 | Polymorphs of pitavastatin calcium In force · From the USPTO record | In force | From the USPTO record | |
| US 9,580,440 | Polymorphs of darunavir In force · From the USPTO record | In force | From the USPTO record | |
| US 9,624,236 | Amorphous darunavir In force · From the USPTO record | In force | From the USPTO record | |
| US 9,024,015 | Process for preparing tolvaptan intermediates In force · From the USPTO record | In force | From the USPTO record | |
| US 9,126,949 | Process for rilpivirine In force · From the USPTO record | In force | From the USPTO record | |
| US 9,968,607 | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,096,556 | Amorphous ritonavir co-precipitated In force · From the USPTO record | In force | From the USPTO record | |
| US 9,233,935 | Rilpivirine hydrochloride In force · From the USPTO record | In force | From the USPTO record | |
| US 9,540,406 | Process for fosaprepitant In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 23: 32 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
38 no status recorded